Videos

“Multidisciplinary discussion is best,” says Shawn Dason, MD, FRCSC.

“IsoPSA is a way of measuring all the different PSA-related proteins in the blood,” says Eric A. Klein, MD.

“Those that did complete the surveys generally reported average improvements in bone-metastasis-related pain and ability to function despite that pain,” says Brian D. Gonzalez, PhD.

Welcome to another installment of Uranimals, a video series featuring urologists and their pets, brought to you by Urology Times. From a trio of doodles to a miniature poodle, let’s see who some of the top medical professionals are spending time with when they’re not in the clinic!

Vivek K. Narayan, MD, MS, shares thoughts on approaching treatment selection of mCSPC and Ashley E. Ross, MD, PhD, comments on the use of relugolix in patients.

Bobby Liaw, MD, reviews the study design and results of the phase 3 ENZAMET study and discusses an ongoing trial in mCSPC, ARASENS.

Ashley E. Ross, MD, PhD, reviews data and study results from the phase 3 TITAN and phase 3 ARCHES trial in mCSPC.

“The prevalence of incontinence is high and increasing. We recommend routine screening for all women for this condition as a part of preventive health care,” says Ushma J. Patel, MD.

“Women often are afraid to ask for what they want because they don't want to be perceived as too aggressive or too bossy,” says Kate H. Kraft, MD.

“IsoPSA is intended to be used in men over 50 who are being screened for prostate cancer as a way of helping to decide whether or not a biopsy should be done,” says Eric A. Klein, MD.

In this video, Ryan J. Nelson, DO, and Steven Ogilvy, PA-C, demonstrate the retroperitoneal single-port robotic surgical technique for a kidney tumor.

“I think the notable finding is the fact that the overall detection rate is very high, even at low PSA levels,” says David M. Schuster, MD, FACR.

“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.

“I think this data are very compelling,” says Neal D. Shore, MD, FACS.

"Intermittent catheterization is an important concept in urology, and it has a long history," says John Stoffel, MD.

Types of patients with muscle invasive bladder cancer who may be candidates for a watch-and-wait approach.

The role of adjuvant therapy in nonmetastatic muscle invasive bladder cancer, and an overview of promising novel therapies in the treatment pipeline.

“We found that while the NCCN guideline for Lynch syndrome is highly specific in identifying patients with Lynch syndrome, it missed about 50% of patients with upper tract cancer who had Lynch syndrome,” says Hong Truong, MD.

“This is one of the first large-scale, and by that, I mean a national-based study throughout the United States, with geographical diversity of community-based urology practices that had a pretty sophisticated background of advanced prostate cancer care,” says Neal D. Shore, MD, FACS.

“These are consistent results that continue to demonstrate a disease-free survival benefit of pembrolizumab adjuvant versus placebo,” says Toni K. Choueiri, MD.

“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.

“I think, in general, patients with hereditary upper tract cancer may be under-recognized and under-referred for genetic evaluation,” says Hong Truong, MD.

“[These favorable findings just speak] to the complexity of the health index for these patients,” says Neal D. Shore, MD, FACS.

“It's the first time that any gene expression test has been analyzed in a randomized trial, even if it's post-hoc, in intermediate-risk patients,” says Daniel E. Spratt, MD.

“There's no question that many patients [undergoing transurethral BPH surgery] can be done as a same-day ambulatory procedure. But you need to look at the criteria as to who you're going to keep and who you're not going to keep,” says Michael A. Palese, MD.

Kelly L. Stratton, MD, FACS, highlights 5 pivotal prostate cancer studies from the 2022 ASCO Genitourinary Cancers Symposium.

Christine Ibilibor, MD, discusses 6 noteworthy abstracts from the 2022 Genitourinary Cancers Symposium.

“I think research is a very important tool,” says Padraic O’Malley, MD, MSc, FRCSC.

"There have been few therapies that have so galvanized management of a urologic condition as what we've witnessed over the past decade regarding the use of onabotulinumtoxinA (Botox) for bladder dysfunction," says Melissa R. Kaufman, MD, PhD, FACS.

First-line treatment options available for patients with high-risk non-muscle invasive bladder cancer and variables that affect treatment decisions.